Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.320
-0.190 (-4.21%)
At close: Mar 6, 2026, 4:00 PM EST
4.240
-0.080 (-1.85%)
After-hours: Mar 6, 2026, 5:09 PM EST
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $861.00K in the quarter ending September 30, 2025, a decrease of -12.77%. This brings the company's revenue in the last twelve months to $2.82M, up 6.46% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.82M
Revenue Growth
+6.46%
P/S Ratio
86.56
Revenue / Employee
$40,257
Employees
70
Market Cap
243.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
| Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
| Dec 31, 2022 | 3.53M | 4.32M | - |
| Dec 31, 2021 | -782.00K | -6.49M | - |
| Dec 31, 2020 | 5.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Silence Therapeutics | 25.83M |
| Prelude Therapeutics | 10.50M |
| Surrozen | 3.60M |
| Abeona Therapeutics | 400.00K |
| Inhibikase Therapeutics | 1.00 |
OBIO News
- 3 days ago - Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT - GlobeNewsWire
- 15 days ago - Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewsWire
- 21 days ago - Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - GlobeNewsWire
- 3 months ago - Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - GlobeNewsWire
- 4 months ago - Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 4 months ago - Orchestra BioMed to Host Business Update Call on November 12, 2025 - GlobeNewsWire
- 4 months ago - Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements - GlobeNewsWire